• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

比伐卢定桥接依诺肝素与磺达肝癸钠在接受直接经皮冠状动脉介入治疗的急性心肌梗死患者中的疗效和安全性：一项单中心研究的证据

Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study.

作者信息

Guo Yanqing, Wang Jingping, Wang Zhixin, Li Li, An Jian

机构信息

Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.

出版信息

Arch Med Sci. 2023 Jan 13;19(1):242-249. doi: 10.5114/aoms/157287. eCollection 2023.

DOI:10.5114/aoms/157287
PMID:36817677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9897106/
Abstract

INTRODUCTION

This study aims to compare the safety and efficacy of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction (AMI) who were undergoing primary percutaneous coronary intervention (PPCI).

METHODS

The study is a prospective, natural, and selective interventional trial based on real-world data for 482 AMI patients.

RESULTS

At the end of the follow-up, the two groups demonstrated similar major adverse cardiovascular and cerebrovascular events (MACCE) and bleeding rates. After propensity score matching (PSM), the fondaparinux group showed greater advantages in reducing MACCE and bleeding events.

CONCLUSIONS

The anticoagulation strategy of bivalirudin bridging fondaparinux seems to be superior to that of bivalirudin bridging enoxaparin in patients with AMI undergoing PPCI.

摘要

引言

本研究旨在比较比伐卢定桥接依诺肝素与磺达肝癸钠在接受直接经皮冠状动脉介入治疗（PPCI）的急性心肌梗死（AMI）患者中的安全性和有效性。

方法

该研究是一项基于482例AMI患者真实世界数据的前瞻性、自然性和选择性干预试验。

结果

随访结束时，两组的主要不良心血管和脑血管事件（MACCE）及出血率相似。倾向评分匹配（PSM）后，磺达肝癸钠组在降低MACCE和出血事件方面显示出更大优势。

结论

在接受PPCI的AMI患者中，比伐卢定桥接磺达肝癸钠的抗凝策略似乎优于比伐卢定桥接依诺肝素的抗凝策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b09e/9897106/d399c125947a/AMS-19-1-157287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b09e/9897106/d399c125947a/AMS-19-1-157287-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b09e/9897106/d399c125947a/AMS-19-1-157287-g001.jpg

相似文献

1
Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study.比伐卢定桥接依诺肝素与磺达肝癸钠在接受直接经皮冠状动脉介入治疗的急性心肌梗死患者中的疗效和安全性：一项单中心研究的证据
Arch Med Sci. 2023 Jan 13;19(1):242-249. doi: 10.5114/aoms/157287. eCollection 2023.
2
Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban.替罗非班治疗经皮冠状动脉介入治疗患者中磺达肝癸钠与依诺肝素的疗效和安全性。
Mil Med Res. 2016 Apr 27;3:13. doi: 10.1186/s40779-016-0081-6. eCollection 2016.
3
Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.比伐卢定与肝素加糖蛋白 IIb/IIIa 抑制剂在经氯吡格雷预处理行经皮冠状动脉介入治疗的非 ST 段抬高型心肌梗死患者中的应用：来自 ACUITY 和 ISAR-REACT 4 试验的汇总分析。
Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.
4
Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.普通肝素、依诺肝素或比伐卢定院前给药对接受ST段抬高型心肌梗死直接经皮冠状动脉介入治疗患者的疗效及安全性：来自ORBI注册研究的见解
Arch Cardiovasc Dis. 2016 Dec;109(12):696-707. doi: 10.1016/j.acvd.2015.10.007. Epub 2016 Nov 3.
5
Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.磺达肝癸钠与依诺肝素对非ST段抬高型心肌梗死患者院内出血及1年死亡率的影响。FAST-MI（法国急性ST段抬高型和非ST段抬高型心肌梗死注册研究）2010年。
Eur Heart J Acute Cardiovasc Care. 2015 Jun;4(3):211-9. doi: 10.1177/2048872614544857. Epub 2014 Jul 29.
6
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.磺达肝癸钠与依诺肝素在接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者中的疗效和安全性：来自OASIS-5试验的结果。
J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51. doi: 10.1016/j.jacc.2007.07.042. Epub 2007 Oct 15.
7
Cost effectiveness of anticoagulation in acute coronary syndromes.急性冠状动脉综合征中的抗凝治疗成本效益。
Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000.
8
Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.急性心肌梗死直接经皮冠状动脉介入治疗期间的抗凝治疗：支架和P2Y12抑制剂时代随机试验的荟萃分析
BMJ. 2014 Nov 11;349:g6419. doi: 10.1136/bmj.g6419.
9
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.急性冠状动脉综合征患者行经皮冠状动脉介入治疗时使用比伐卢定：来自急性导管插入术和紧急干预分诊策略（ACUITY）试验的亚组分析
Lancet. 2007 Mar 17;369(9565):907-19. doi: 10.1016/S0140-6736(07)60450-4.
10
Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.比伐卢定与肝素联合或不联合糖蛋白 IIb/IIIa 抑制剂用于行直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者：来自 HORIZONS-AMI 和 EUROMAX 试验的汇总患者水平分析。
J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029.

本文引用的文献

1
Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.比伐卢定联合高剂量输注与肝素单药治疗在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中的随机试验。
Lancet. 2022 Nov 26;400(10366):1847-1857. doi: 10.1016/S0140-6736(22)01999-7. Epub 2022 Nov 6.
2
Trends in Bleeding Events Among Patients With Acute Coronary Syndrome in China, 2015 to 2019: Insights From the CCC-ACS Project.2015至2019年中国急性冠状动脉综合征患者出血事件趋势：来自CCC-ACS项目的见解
Front Cardiovasc Med. 2021 Dec 13;8:769165. doi: 10.3389/fcvm.2021.769165. eCollection 2021.
3
Concomitant multi-vessel disease is associated with a lower procedural death rate in patients treated with percutaneous coronary interventions within the left main coronary artery (from the ORPKI registry).
在接受经皮冠状动脉介入治疗的左主干冠状动脉患者中（来自ORPKI注册研究），合并多支血管病变与较低的手术死亡率相关。
Arch Med Sci. 2019 Jun 22;17(4):881-890. doi: 10.5114/aoms.2019.82666. eCollection 2021.
4
Effectiveness of fondaparinux vs unfractionated heparin following percutaneous coronary intervention in survivors of out-of-hospital cardiac arrest due to acute myocardial infarction.在因急性心肌梗死导致院外心脏骤停的幸存者中，经皮冠状动脉介入治疗后磺达肝癸钠与普通肝素的疗效比较。
Eur J Clin Pharmacol. 2021 Oct;77(10):1563-1567. doi: 10.1007/s00228-021-03152-7. Epub 2021 May 8.
5
Combinations of bleeding and ischemic risk and their association with clinical outcomes in acute coronary syndrome.急性冠脉综合征中出血和缺血风险的组合及其与临床结局的关系。
Int J Cardiol. 2019 Sep 1;290:7-14. doi: 10.1016/j.ijcard.2019.05.035. Epub 2019 May 21.
6
Nicorandil prior to primary percutaneous coronary intervention improves clinical outcomes in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.在直接经皮冠状动脉介入治疗前使用尼可地尔可改善急性心肌梗死患者的临床结局：一项随机对照试验的荟萃分析。
Drug Des Devel Ther. 2019 Apr 29;13:1389-1400. doi: 10.2147/DDDT.S195918. eCollection 2019.
7
Bivalirudin for patients with STEMI at high risk of bleeding undergoing PPCI.比伐卢定用于接受直接经皮冠状动脉介入治疗（PPCI）且有高出血风险的ST段抬高型心肌梗死（STEMI）患者。
Nat Rev Cardiol. 2017 Sep 14;14(10):626. doi: 10.1038/nrcardio.2017.141.
8
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.比伐卢定与肝素单药治疗心肌梗死的比较。
N Engl J Med. 2017 Sep 21;377(12):1132-1142. doi: 10.1056/NEJMoa1706443. Epub 2017 Aug 27.
9
Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.在急性冠状动脉综合征患者管理中选择依诺肝素和磺达肝癸钠：一项系统评价和荟萃分析。
BMC Cardiovasc Disord. 2017 May 8;17(1):116. doi: 10.1186/s12872-017-0552-z.
10
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.比伐卢定与肝素联合或不联合替罗非班用于急性心肌梗死患者经皮冠状动脉介入治疗的 BRIGHT 随机临床试验。
JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.